JP2014513725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513725A5 JP2014513725A5 JP2014511457A JP2014511457A JP2014513725A5 JP 2014513725 A5 JP2014513725 A5 JP 2014513725A5 JP 2014511457 A JP2014511457 A JP 2014511457A JP 2014511457 A JP2014511457 A JP 2014511457A JP 2014513725 A5 JP2014513725 A5 JP 2014513725A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- infection
- stimulating
- viral infection
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 20
- 208000036142 Viral infection Diseases 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 230000009385 viral infection Effects 0.000 claims description 13
- 230000003834 intracellular effect Effects 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 230000004936 stimulating effect Effects 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 8
- 229960001438 immunostimulant agent Drugs 0.000 claims description 7
- 239000003022 immunostimulating agent Substances 0.000 claims description 7
- 230000003308 immunostimulating effect Effects 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 6
- 208000028172 protozoa infectious disease Diseases 0.000 claims description 5
- -1 polymorph Chemical class 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 102000005348 Neuraminidase Human genes 0.000 claims description 3
- 108010006232 Neuraminidase Proteins 0.000 claims description 3
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 208000002672 hepatitis B Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 241000223935 Cryptosporidium Species 0.000 claims description 2
- 241000222722 Leishmania <genus> Species 0.000 claims description 2
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 208000010362 Protozoan Infections Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 241000223997 Toxoplasma gondii Species 0.000 claims description 2
- 241000223104 Trypanosoma Species 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 229960002480 nitazoxanide Drugs 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000002911 sialidase inhibitor Substances 0.000 claims description 2
- FDTZUTSGGSRHQF-UHFFFAOYSA-N Desacetyl-nitazoxanide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 FDTZUTSGGSRHQF-UHFFFAOYSA-N 0.000 claims 1
- 206010037075 Protozoal infections Diseases 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 36
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003904 antiprotozoal agent Substances 0.000 description 2
- 229960002751 imiquimod Drugs 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical group C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229950010550 resiquimod Drugs 0.000 description 2
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- XNYZHCFCZNMTFY-UHFFFAOYSA-N diminazene Chemical compound C1=CC(C(=N)N)=CC=C1N\N=N\C1=CC=C(C(N)=N)C=C1 XNYZHCFCZNMTFY-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 229950004244 laninamivir Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229940053382 meglumine antimonate Drugs 0.000 description 1
- XOGYVDXPYVPAAQ-SESJOKTNSA-M meglumine antimoniate Chemical compound O[Sb](=O)=O.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO XOGYVDXPYVPAAQ-SESJOKTNSA-M 0.000 description 1
- MGEOLZFMLHYCFZ-UHFFFAOYSA-N melarsomine Chemical compound C1=CC([As](SCCN)SCCN)=CC=C1NC1=NC(N)=NC(N)=N1 MGEOLZFMLHYCFZ-UHFFFAOYSA-N 0.000 description 1
- BQQYXPHRXIZMDM-UHFFFAOYSA-N n-Demethylated piperazine Chemical compound C1=C(NC=2N=C(C=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)C(C=C1)=CC=C1CN1CCNCC1 BQQYXPHRXIZMDM-UHFFFAOYSA-N 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 description 1
- 229960001084 peramivir Drugs 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- YQDGWZZYGYKDLR-UZVLBLASSA-K sodium stibogluconate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].O1[C@H]([C@H](O)CO)[C@H](O2)[C@H](C([O-])=O)O[Sb]21([O-])O[Sb]1(O)(O[C@H]2C([O-])=O)O[C@H]([C@H](O)CO)[C@@H]2O1 YQDGWZZYGYKDLR-UZVLBLASSA-K 0.000 description 1
- 229960001567 sodium stibogluconate Drugs 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486728P | 2011-05-16 | 2011-05-16 | |
| US61/486,728 | 2011-05-16 | ||
| PCT/US2012/037958 WO2012158699A1 (en) | 2011-05-16 | 2012-05-15 | Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017087529A Division JP2017149764A (ja) | 2011-05-16 | 2017-04-26 | ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513725A JP2014513725A (ja) | 2014-06-05 |
| JP2014513725A5 true JP2014513725A5 (enExample) | 2015-07-02 |
| JP6138764B2 JP6138764B2 (ja) | 2017-05-31 |
Family
ID=47175068
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014511457A Expired - Fee Related JP6138764B2 (ja) | 2011-05-16 | 2012-05-15 | ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用 |
| JP2017087529A Withdrawn JP2017149764A (ja) | 2011-05-16 | 2017-04-26 | ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用 |
| JP2018226678A Pending JP2019052175A (ja) | 2011-05-16 | 2018-12-03 | ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017087529A Withdrawn JP2017149764A (ja) | 2011-05-16 | 2017-04-26 | ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用 |
| JP2018226678A Pending JP2019052175A (ja) | 2011-05-16 | 2018-12-03 | ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20120294831A1 (enExample) |
| EP (1) | EP2709453B1 (enExample) |
| JP (3) | JP6138764B2 (enExample) |
| KR (1) | KR102037162B1 (enExample) |
| CN (2) | CN107096032A (enExample) |
| AU (1) | AU2012255962B2 (enExample) |
| BR (1) | BR112013029505A2 (enExample) |
| CA (1) | CA2836253C (enExample) |
| DK (1) | DK2709453T3 (enExample) |
| EA (1) | EA024063B1 (enExample) |
| ES (1) | ES2767304T3 (enExample) |
| IL (1) | IL229459B (enExample) |
| MX (2) | MX2013013115A (enExample) |
| WO (1) | WO2012158699A1 (enExample) |
| ZA (1) | ZA201308617B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107096032A (zh) * | 2011-05-16 | 2017-08-29 | 罗马克实验室有限公司 | 在有需要的对象中刺激免疫应答的方法 |
| CN105683392A (zh) * | 2013-03-15 | 2016-06-15 | 博德研究所 | 树突细胞应答基因表达、物质组合物及其使用方法 |
| WO2015030504A1 (ko) * | 2013-09-02 | 2015-03-05 | 가톨릭대학교 산학협력단 | 비소세포폐암 치료제를 유효성분으로 포함하는 톡소포자충감염증의 예방 또는 치료용 약학 조성물 |
| KR101508610B1 (ko) * | 2013-09-02 | 2015-04-08 | 가톨릭대학교 산학협력단 | 다코미티닙을 포함하는 톡소포자충 감염증의 예방 및 치료용 조성물 |
| KR101508611B1 (ko) | 2013-09-02 | 2015-04-08 | 가톨릭대학교 산학협력단 | 아파티닙을 포함하는 톡소포자충 감염증의 예방 및 치료용 조성물 |
| BR112017009651A2 (pt) | 2014-11-11 | 2017-12-19 | Romark Laboratories Lc | composto, composição farmacêutica, e, método para tratamento de uma infecção por protozoário intracelular, uma infecção viral ou um câncer. |
| US20180098972A1 (en) * | 2015-01-26 | 2018-04-12 | Children's Medical Center Corporation | Treatment of infectious diseases |
| PT3436074T (pt) | 2016-03-31 | 2020-08-21 | Romark Laboratories Lc | Compostos tiazolida para tratamento de infeções virais |
| SG11201808402RA (en) | 2016-04-11 | 2018-10-30 | Genfit | Methods of treatment for cholestatic and fibrotic diseases |
| CN105998036B (zh) * | 2016-05-19 | 2018-07-27 | 洛阳市兽药厂 | 一种猪禽用复方磺胺硝唑尼特可溶性粉 |
| US11173149B2 (en) | 2017-04-18 | 2021-11-16 | Romark Laboratories L.C. | Inhibition of protein disulfide-isomerase A3 |
| EP3709985A1 (en) * | 2017-11-17 | 2020-09-23 | Köster, Hubert | [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate for use in lymphangioleiomyomatosis and other diseases |
| JP2022528727A (ja) * | 2019-04-12 | 2022-06-15 | ジェンフィット | 酸化ストレスに関連する疾患の治療に使用するためのニタゾキサニド及びチアゾリド |
| ES2991100T3 (es) | 2019-07-26 | 2024-12-02 | Espervita Therapeutics Inc | Acidos monocarboxílicos y dicarboxílicos de hidrocarburos de cadena larga funcionalizados útiles para la prevención o el tratamiento de enfermedades |
| CN113398125B (zh) * | 2020-03-16 | 2024-05-03 | 绍兴君科臻元医药科技有限公司 | 替唑尼特药物组合物及其医药用途 |
| EP4182304A1 (en) | 2020-07-20 | 2023-05-24 | Romark Laboratories, L.C. | Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine |
| JP2023538136A (ja) | 2020-08-24 | 2023-09-06 | ロマーク ラボラトリーズ，リミティド カンパニー | コロナウイルスに対するチアゾリドの利用 |
| TW202245804A (zh) | 2021-01-25 | 2022-12-01 | 美商艾斯佩維他治療學公司 | 官能化長鏈烴單羧酸及二羧酸及其衍生物以及其於預防或治療疾病之用途 |
| CA3209453A1 (en) | 2021-01-25 | 2022-07-28 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives therof, and their use for the prevention or treatment of disease |
| WO2023077711A1 (zh) * | 2021-11-03 | 2023-05-11 | 南方科技大学 | 预防前列腺癌的药剂的筛选方法及硝唑尼特在制药中的应用 |
| CN114231611A (zh) * | 2021-12-07 | 2022-03-25 | 中南大学湘雅二医院 | 干扰素诱导基因ifit3对b淋巴细胞活化及分化影响的研究方法 |
| CN116539887A (zh) * | 2023-01-09 | 2023-08-04 | 重庆医科大学 | Psme1作为药物靶点在筛选或制备治疗乙型肝炎的药物中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859038A (en) * | 1994-09-08 | 1999-01-12 | Romark Laboratories, L.C. | Method for treatment of helicobacter pylori infections |
| US5968961A (en) | 1997-05-07 | 1999-10-19 | Romark Laboratories, L.C. | Pharmaceutical compositions of tizoxanide and nitazoxanide |
| US5965590A (en) * | 1994-09-08 | 1999-10-12 | Romark Lab Lc | Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide |
| MX9604483A (es) | 1994-09-08 | 1998-02-28 | Jean-Francois Rossignol | Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas. |
| US5958038A (en) * | 1997-11-07 | 1999-09-28 | S3 Incorporated | Computer processor with two addressable memories and two stream registers and method of data streaming of ALU operation |
| US5935591A (en) | 1998-01-15 | 1999-08-10 | Romark Laboratories, L.C. | Method for treatment of equine protozoal myeloencephalitis with thiazolides |
| US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| UA90864C2 (en) | 2004-09-09 | 2010-06-10 | Ромарк Лебораториз, Л.К. | Halogenated benzamide derivatives |
| EP2047850A3 (en) | 2005-04-12 | 2009-07-29 | Romark Laboratories, L.C. | Methods for treating diseases through inhibition of the function of molecular chaperones such as protein disulfide isomerases , pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents |
| CA2636527C (en) * | 2006-01-09 | 2016-05-17 | Romark Laboratories, L.C. | Viral hepatitis treatment |
| WO2009071633A1 (en) * | 2007-12-06 | 2009-06-11 | Glaxosmithkline Biologicals S.A. | Influenza composition |
| US20100081713A1 (en) * | 2008-03-19 | 2010-04-01 | CombinatoRx, (Singapore) Pte. Ltd. | Compositions and methods for treating viral infections |
| WO2010077634A1 (en) * | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EA030679B1 (ru) * | 2009-06-26 | 2018-09-28 | РОМАРК ЛЭБОРЕТЕРИЗ Эл.Си. | Соединения и способы лечения гриппа |
| WO2011009961A1 (en) * | 2009-07-24 | 2011-01-27 | Virologik Gmbh | Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis |
| CA2777824C (en) * | 2009-10-22 | 2016-11-29 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
| US20110223131A1 (en) * | 2010-02-24 | 2011-09-15 | Gilead Sciences, Inc. | Antiviral compounds |
| US9439878B2 (en) * | 2010-06-03 | 2016-09-13 | Douglas Tyler McKenzie | Use of lumefantrine and related compounds in the treatment of cancer |
| CA2832818A1 (en) * | 2011-04-06 | 2012-10-11 | The Trustees Of Princeton University | Anti-viral combination therapy |
| CN107096032A (zh) * | 2011-05-16 | 2017-08-29 | 罗马克实验室有限公司 | 在有需要的对象中刺激免疫应答的方法 |
-
2012
- 2012-05-15 CN CN201611145115.5A patent/CN107096032A/zh active Pending
- 2012-05-15 MX MX2013013115A patent/MX2013013115A/es unknown
- 2012-05-15 BR BR112013029505-8A patent/BR112013029505A2/pt active Search and Examination
- 2012-05-15 US US13/471,948 patent/US20120294831A1/en not_active Abandoned
- 2012-05-15 AU AU2012255962A patent/AU2012255962B2/en not_active Ceased
- 2012-05-15 CN CN201280035142.0A patent/CN103648282B/zh not_active Expired - Fee Related
- 2012-05-15 CA CA2836253A patent/CA2836253C/en not_active Expired - Fee Related
- 2012-05-15 EP EP12786263.9A patent/EP2709453B1/en active Active
- 2012-05-15 ES ES12786263T patent/ES2767304T3/es active Active
- 2012-05-15 KR KR1020137031365A patent/KR102037162B1/ko not_active Expired - Fee Related
- 2012-05-15 DK DK12786263.9T patent/DK2709453T3/da active
- 2012-05-15 MX MX2018009061A patent/MX378726B/es unknown
- 2012-05-15 EA EA201391616A patent/EA024063B1/ru not_active IP Right Cessation
- 2012-05-15 JP JP2014511457A patent/JP6138764B2/ja not_active Expired - Fee Related
- 2012-05-15 WO PCT/US2012/037958 patent/WO2012158699A1/en not_active Ceased
-
2013
- 2013-11-14 IL IL229459A patent/IL229459B/en active IP Right Grant
- 2013-11-15 ZA ZA2013/08617A patent/ZA201308617B/en unknown
-
2017
- 2017-04-26 JP JP2017087529A patent/JP2017149764A/ja not_active Withdrawn
-
2018
- 2018-01-03 US US15/861,234 patent/US10336058B2/en not_active Expired - Fee Related
- 2018-12-03 JP JP2018226678A patent/JP2019052175A/ja active Pending
-
2019
- 2019-06-12 US US16/438,783 patent/US10814612B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513725A5 (enExample) | ||
| JP2012531420A5 (enExample) | ||
| RU2019126746A (ru) | Способы лечения гриппа | |
| JP2020506243A5 (enExample) | ||
| IL321503A (en) | Recombinant virus, composition comprising the same, and uses thereof | |
| JP2017517578A5 (enExample) | ||
| SI2709613T1 (en) | Procedures for the treatment of HCV | |
| HRP20230274T1 (hr) | Kemijski spojevi | |
| JP2014515406A5 (enExample) | ||
| JP2013231081A5 (enExample) | ||
| HRP20240168T1 (hr) | Kombinacije dolutegravira i lamivudina za liječenje hiv infekcije | |
| JP2009535352A5 (enExample) | ||
| JP2016530314A5 (enExample) | ||
| HRP20130163T1 (hr) | Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba | |
| JP2018520352A5 (enExample) | ||
| IN2012DN01254A (enExample) | ||
| MD20150092A2 (ro) | Derivate ale amidelor pentru tratamentul infecţiei cu HIV | |
| TN2012000009A1 (en) | Pharmaceutical composition for a hepatitis c viral protease inhibitor | |
| JP2012513479A5 (enExample) | ||
| MA35414B1 (fr) | Formulations de vaccin parenteral contre un norovirus | |
| SI2477987T1 (en) | MODULATORS TO TOLL OF LIKE RECEPTORS | |
| RU2012102373A (ru) | Адъювантная композиция, содержащая наночастицы поли-гамма-глутаминовой кислоты-хитозан | |
| JP2014510130A5 (enExample) | ||
| JP2014532722A5 (enExample) | ||
| JP2019506390A5 (enExample) |